Drug intelligence / Profile preview

dapoxetine + folic acid

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

A combination pharmaceutical treatment consisting of dapoxetine and folic acid, primarily used for the management of premature ejaculation. Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) that enhances serotonin signaling in nerves responsible for ejaculation, thus prolonging ejaculation time. The addition of folic acid appears to potentially improve the efficacy of dapoxetine treatment in patients with premature ejaculation.

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on dapoxetine + folic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dapoxetine + folic acid.

Explore the full profile